Business
Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results
Strong Financial and Operational Performance in the Second Quarter Total Revenues Increased 5% Compared to Second Quarter 2019 2020 Total Revenue Guidance
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Strong Financial and Operational Performance in the Second Quarter\n Total Revenues Increased 5% Compared to Second Quarter 2019\n 2020 Total Revenue Guidance Increased to a Range of $2.225 Billion to $2.325 Billion\n 2020 GAAP EPS Guidance Increased to $3.40 - $4.85\n 2020 Adjusted EPS Guidance Increased to $11.90 - $13.00\n On Track to Deliver Diversified Top-line Growth with up to Five Product Launches Through 2021\n\n\nDUBLIN, Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance.\n\"I am proud that we delivered strong financial and operational results above our expectations despite challenges arising from the COVID-19 pandemic,\" said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. \"With the strong performance of Xyrem and the recent FDA approval of Xywav, we are well-positioned to ensure the durability and growth of our oxybate business with differentiated products.\" \n\"The second quarter was highlighted by the approval of Zepzelca, and our subsequent strong launch, which was accomplished within six months of closing the licensing agreement with PharmaMar,\" continued Mr. Cozadd. \"We also innovated around the challenges of the pandemic, pivoting to a timely virtual launch of Sunosi in Germany and implementing robust measures to facilitate continued progress of our clinical development programs and regulatory filings.\" \n\"Through the issuance of $1 billion of senior notes in the second quarter, we strengthened our financial position and increased our capacity for a broader set of corporate development opportunities,\" concluded Mr. Cozadd. \"With multiple commercial launches, the expansion of our innovative pipeline, strategic capital allocation, and projected durable revenue growth and diversification, this is a transformative year for us, and we are excited about the opportunities ahead for patients and shareholders.\"\nThe company is on track to execute up to five key launches through 2020 and 2021:\nEuropean rolling launch of Sunosi (initiated May 2020); U.S. launch of Zepzelca (initiated July 2020); U.S. launch of Xywav in the fourth quarter of 2020 following the implementation of the risk evaluation and mitigation strategy (REMS); U.S. launch of JZP-458 (recombinant ...